Get the Stockscreener App
2.72
0.73%
-0.02
After Hours:
2.82
0.10
+3.68%
Eledon Pharmaceuticals Inc stock is traded at $2.72, with a volume of 671.86K.
It is down -0.73% in the last 24 hours and up +12.40% over the past month.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
See More
Previous Close:
$2.74
Open:
$2.75
24h Volume:
671.86K
Relative Volume:
0.76
Market Cap:
$162.88M
Revenue:
-
Net Income/Loss:
$-40.33M
P/E Ratio:
-1.5196
EPS:
-1.79
Net Cash Flow:
$-39.53M
1W Performance:
-4.90%
1M Performance:
+12.40%
6M Performance:
-7.48%
1Y Performance:
+1.49%
1-Day Range:
$2.66
$2.81
1-Week Range:
$2.66
$3.00
52-Week Range:
$2.315
$5.54
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Name
Eledon Pharmaceuticals Inc
Sector
Industry
Phone
949-238-8090
Address
19800 MACARTHUR BLVD., IRVINE
Compare ELDN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
2.72 | 164.08M | 0 | -40.33M | -39.53M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Guggenheim | Buy |
| May-13-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-23-21 | Initiated | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Stock (ELDN) Latest News
Is Eledon Pharmaceuticals Inc. stock a buy in volatile marketsJuly 2025 Weekly Recap & Stock Portfolio Risk Control - newser.com
Has Eledon Pharmaceuticals Inc. found a price floorTrade Volume Summary & Short-Term High Return Ideas - newser.com
Published on: 2025-10-13 09:50:08 - newser.com
What risks investors should watch in Eledon Pharmaceuticals Inc. stock2025 Technical Patterns & Safe Capital Growth Trade Ideas - newser.com
Using R and stats models for Eledon Pharmaceuticals Inc. forecastingEarnings Recap Summary & AI Enhanced Trading Alerts - newser.com
Quantitative breakdown of Eledon Pharmaceuticals Inc. recent moveMarket Activity Summary & Accurate Entry/Exit Alerts - newser.com
Why analysts remain bullish on Eledon Pharmaceuticals Inc. stockWeekly Trade Report & Weekly Hot Stock Watchlists - newser.com
Eledon Pharmaceuticals Inc. stock chart pattern explainedJobs Report & Daily Entry Point Alerts - newser.com
Published on: 2025-10-12 23:02:34 - newser.com
Key metrics from Eledon Pharmaceuticals Inc.’s quarterly dataMarket Sentiment Report & Verified Swing Trading Watchlist - newser.com
Real time pattern detection on Eledon Pharmaceuticals Inc. stockJuly 2025 Weekly Recap & Low Risk High Reward Trade Ideas - newser.com
Has Eledon Pharmaceuticals Inc. formed a bullish divergenceTrade Exit Summary & Community Consensus Trade Signals - newser.com
How strong is Eledon Pharmaceuticals Inc. (2TK) stock earnings growthJuly 2025 Outlook & High Accuracy Trade Alerts - newser.com
Eledon Pharmaceuticals' (ELDN) "Sell (D)" Rating Reiterated at Weiss Ratings - MarketBeat
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) is largely controlled by institutional shareholders who own 51% of the company - Yahoo Finance
Evaluating Eledon Pharmaceuticals Inc. with trendline analysis2025 Institutional Moves & Real-Time Stock Movement Alerts - newser.com
Eledon Pharmaceuticals Inc. stock trend outlook and recovery pathLong Setup & Safe Capital Growth Stock Tips - newser.com
What technical models suggest about Eledon Pharmaceuticals Inc.’s comebackQuarterly Earnings Report & Safe Capital Growth Tips - newser.com
Will Eledon Pharmaceuticals Inc. stock return to pre crisis levelsProduct Launch & Real-Time Buy Signal Notifications - newser.com
Is Eledon Pharmaceuticals Inc 2TK a good long term investmentStock Rotation Strategies & Superior Portfolio Growth - earlytimes.in
Is Eledon Pharmaceuticals Inc. forming a bottoming baseWeekly Risk Summary & Daily Price Action Insights - newser.com
Published on: 2025-10-06 03:44:24 - newser.com
What technical patterns form on Eledon Pharmaceuticals Inc. (2TK) stock chartsJuly 2025 News Drivers & Consistent Growth Stock Picks - newser.com
Can you recover from losses in Eledon Pharmaceuticals Inc.July 2025 Update & Free Real-Time Market Sentiment Alerts - newser.com
Using data tools to time your Eledon Pharmaceuticals Inc. exitPortfolio Risk Summary & Entry and Exit Point Strategies - newser.com
Is Eledon Pharmaceuticals Inc. (2TK) stock inflation resilientJuly 2025 Short Interest & AI Powered Buy and Sell Recommendations - newser.com
Will Eledon Pharmaceuticals Inc. (2TK) stock keep raising dividendsDay Trade & Weekly Breakout Watchlists - newser.com
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Why Eledon Pharmaceuticals Inc. (2TK) stock trades below fair valueQuarterly Investment Review & Free Expert Approved Momentum Trade Ideas - newser.com
Using Ichimoku Cloud for Eledon Pharmaceuticals Inc. technicalsQuarterly Portfolio Report & Consistent Return Strategy Ideas - newser.com
Is Eledon Pharmaceuticals Inc. (2TK) stock a safe buy pre earningsPortfolio Value Report & Free Weekly Watchlist of Top Performers - newser.com
Eledon Pharmaceuticals Inc Stock (ELDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):